Pay in 4 interest-free payments of $25.62 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
28)29)23(16-4-3-5-20(12-16)34-2)35-21-10-11-22-17(13-21)14-30-32(22)19-8-6-18(26)7-9-19/h3-15
is a novel oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity
HeLa cells treated with 50 μM BTB-1 reveals severe defects in spindle morphology and chromosome alignment
InChiKey: OUQVKRKGTAUJQA-UHFFFAOYSA-N
A notable feature of ML323 is that it simultaneously targets two major DNA damage response pathways (TLS and FA) by inhibiting a common deubiquitinase
NS-2028 0280 28)29)23(16-4-3-5-20(12-16)34-2)35-21-10-11-22-17(13-21)14-30-32(22)19-8-6-18(26)7-9-19/h3-15NS 2028 is a potent soluble guanylyl cyclase (sGC) inhibitor (Ki = 8 nM). It blocks sGC activity in murine cerebellum induced by S nitroso glutathione and NMDA (IC50 values are 17 and 20 nM respectively). NS 2028 also inhibits VEGF induced cGMP accumulation. Product information CAS Number: 204326 43 2 Molecular Weight: 269. 05 Formula: C9H5BrN2O3 Synonym: NS 2028 NS2028 Chemical Name: 8 bromo 4H [1, 2, 4]oxadiazolo[3, 4 c][1, 4]benzoxazin 1 one
US$ 68.00
US$ 42.50
US$ 90.00
US$ 22.50
US$ 84.50
US$ 3250.00
US$ 50.00
US$ 110.00
US$ 110.00
US$ 895.00
US$ 145.00
US$ 40.00
US$ 66.00
US$ 147.50
US$ 147.50
US$ 40.95